The landscape of cell therapy manufacturing is on the brink of transformation as Cellares, an Integrated Development and Manufacturing Organization (IDMO), partners with Sony Corporation to integrate advanced cell analysis and sorting technologies into an already sophisticated manufacturing
The ongoing legal battle between MMJ BioPharma Cultivation and the Drug Enforcement Administration (DEA) exemplifies the hurdles faced by companies attempting to break into pharmaceutical-grade cannabis research. MMJ BioPharma has encountered significant bureaucratic delays, stalling their efforts
The world of cell therapy manufacturing is on the verge of a significant transformation. The partnership between Cellares, a leader in automated cell therapy manufacturing, and Sony Corporation, a technological giant renowned for its advanced flow cytometry, promises to reshape this burgeoning
Investors often seek avenues that can offer significant returns while mitigating risks. The biopharma sector, with its blend of innovation and high stakes, has captured the attention of hedge fund managers and investors alike. But can biopharma hedge funds truly be the key to outperforming the
The ongoing evolution of digital technologies offers the potential to profoundly transform the Australian healthcare system, and this promise is becoming increasingly evident. Published by Cosmos, the article explores the significant advancements in artificial intelligence (AI), digital twins, and
Bain Capital Life Sciences has made headlines with the closure of its new $3 billion biotech fund, the largest in its seven-year history. This monumental step aligns with the firm's continuous efforts since its inception in 2016 to bolster the biotech sector by funding ventures that address unmet
Agilent Technologies Inc. has unveiled its new Biopharma CDx Services Lab (BCSL) in Carpinteria, California, marking a significant stride in the field of precision medicine. This state-of-the-art facility is poised to revolutionize the drug development process by streamlining the journey from early
In a notable turn of events, Allspring Global Investments Holdings LLC has dramatically boosted its stake in Xeris Biopharma Holdings, a leading biopharmaceutical company known for its innovative therapies for patients with unmet medical needs. Documented in the latest Form 13F filing with the
Sarepta Therapeutics recently revealed financial results that indicate lower-than-expected sales for its flagship gene therapy product, Elevidys, designed to treat Duchenne muscular dystrophy (DMD). The sales figures for the second quarter fell short of Wall Street's projections, raising concerns
In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning
